The therapeutic potential of interleukin-6 hyperagonists and antagonists. - sprookjes - yvandenbroek - TriplyDB

The therapeutic potential of interleukin-6 hyperagonists and antagonists.

The therapeutic potential of interleukin-6 hyperagonists and antagonists.

http://www.wikidata.org/entity/Q34430168

about

Receptor recognition sites of cytokines are organized as exchangeable modules. Transfer of the leukemia inhibitory factor receptor-binding site from ciliary neurotrophic factor to interleukin-6.IL-6 type cytokine receptor complexes: hexamer, tetramer or both?Neural activities of IL-6-type cytokines often depend on soluble cytokine receptors.Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling.Patented cancer vaccines: the promising leads.Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells.Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice.Recombinant human single chain Fv antibodies recognizing human interleukin-6. Specific targeting of cytokine-secreting cells.

P2860

Q30322247-889933AC-EC07-4C4F-82AE-E15BD419BBA2 Q33737244-AE12DC05-EC9B-4D20-B811-3A7F5B6796F5 Q33746118-6C465D0E-3CB0-477D-ADAA-20EB498E93C1 Q36576467-B58F4471-EE1D-4740-9D68-3F63AE8D2E7A Q37719552-EF6C46BB-1670-4506-BE6E-0A8A404506A3 Q38328537-55A00622-AF47-4350-9BB4-12D1595DDBF8 Q41869575-8F278EE2-6C0B-4D8B-88F1-EA15C4B1DF7A Q54376679-D08488D3-685B-428A-BA80-2AF77DFF14C0

P2860

The therapeutic potential of interleukin-6 hyperagonists and antagonists.

http://www.wikidata.org/entity/Q34430168

description

1997 nî lūn-bûn

@nan

1997 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի մարտին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年学术文章

@wuu

1997年学术文章

@zh-cn

1997年学术文章

@zh-hans

1997年学术文章

@zh-my

1997年学术文章

@zh-sg

1997年學術文章

@yue

name

The therapeutic potential of interleukin-6 hyperagonists and antagonists.

@ast

The therapeutic potential of interleukin-6 hyperagonists and antagonists.

@en

The therapeutic potential of interleukin-6 hyperagonists and antagonists.

@nl

type

label

The therapeutic potential of interleukin-6 hyperagonists and antagonists.

@ast

The therapeutic potential of interleukin-6 hyperagonists and antagonists.

@en

The therapeutic potential of interleukin-6 hyperagonists and antagonists.

@nl

prefLabel

The therapeutic potential of interleukin-6 hyperagonists and antagonists.

@ast

The therapeutic potential of interleukin-6 hyperagonists and antagonists.

@en

The therapeutic potential of interleukin-6 hyperagonists and antagonists.

@nl

P1433

Q34430168-5C2B66C0-F912-4395-912D-477CB1843B1C

P1476

Q34430168-83009B23-0CF2-40BD-A5E6-A9975F8539ED

P2093

Q34430168-10502F71-F25A-45F6-911C-BCA3DA3427B6

Q34430168-8C7EB08B-6D18-477F-A57A-32386FC4613F

Q34430168-C8E19B2D-D761-47EC-83C8-E1351DB8B3F5

P2860

Q34430168-083394EB-B43C-4349-9FE3-42785032EE0F

Q34430168-0E5AB162-B8B9-49FB-B18E-21F63E2693BF

Q34430168-121F97CD-28B4-4719-88E3-7DB529DAE0B6

Q34430168-151F8DEB-463B-4D50-8947-19A304A84128

Q34430168-158FA663-5030-44CD-92FE-74A2DE4970E3

Q34430168-179A84FE-7961-4BE9-B329-981688E7558A

Q34430168-19C8ECA1-1FAB-41E1-9B62-07A155F90DA9

Q34430168-1D35059C-D2A5-458C-A265-1CB8C2A36912

Q34430168-228A13CA-D0B0-49C6-947E-39F79300CB6B

Q34430168-2665F962-75D0-40D7-A81B-D816B0A238B7

P304

Q34430168-D2BDC916-1A86-48AE-ACA2-648D99F29A7A

P31

Q34430168-B9D33CC4-0A75-4AD2-B7FE-530800275E27

P356

Q34430168-9C14A710-E035-411C-B240-6B760316CD40

P407

Q34430168-1B402103-BEBA-42D3-A396-E97792B3D85B

P433

Q34430168-980CB176-AAC2-4C5E-945E-64C4107E9129

P478

Q34430168-5B3A14F0-51AA-4A41-9FA1-1D0DEA34654B

P577

Q34430168-91800798-78E4-4121-8C1E-19CF783F07AB

P698

Q34430168-3E79F70D-BFDB-4D33-9AF6-2BC7FAC66B73

P921

Q34430168-e9cf79ea-804f-4a65-a0c4-826bd2f2b98b

P356

13543784.6.3.237

P1433

Expert Opinion on Investigational Drugs

P1476

The therapeutic potential of interleukin-6 hyperagonists and antagonists.

@en

P2093

Kallen KJ

http://www.w3.org/2001/XMLSchema#string

Rose-John S

http://www.w3.org/2001/XMLSchema#string

zum Büschenfelde KH

http://www.w3.org/2001/XMLSchema#string

P2860

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

Human growth hormone and extracellular domain of its receptor: crystal structure of the complex

Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M

Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas

Immunoglobulin D enhances the release of tumor necrosis factor-alpha, and interleukin-1 beta as well as interleukin-1 receptor antagonist from human mononuclear cells.

Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus.

Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study.

P304

237-266

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.6.3.237

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

1997-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15989626

http://www.w3.org/2001/XMLSchema#string

P921